Analyzing Shattuck Labs (NASDAQ:STTK) and Immuneering (NASDAQ:IMRX)

Shattuck Labs (NASDAQ:STTK) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Shattuck Labs and Immuneering, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	0	3	2	2	2.86
Immuneering	1	0	4	0	2.60

Shattuck Labs presently has a consensus target price of $4.00, suggesting a potential upside of 70.21%. Immuneering has a consensus target price of $13.75, suggesting a potential upside of 48.97%. Given Shattuck Labs’ stronger consensus rating and higher probable upside, research analysts clearly believe Shattuck Labs is more favorable than Immuneering.

Insider & Institutional Ownership

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 12.0% of Shattuck Labs shares are held by company insiders. Comparatively, 22.9% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Shattuck Labs and Immuneering’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-81.80%	-71.46%
Immuneering	N/A	-146.28%	-117.22%

Valuation & Earnings

This table compares Shattuck Labs and Immuneering”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$5.72 million	19.68	-$75.41 million	($1.21)	-1.94
Immuneering	$320,000.00	1,199.03	-$61.04 million	($1.89)	-4.88

Immuneering has lower revenue, but higher earnings than Shattuck Labs. Immuneering is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Shattuck Labs has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Immuneering has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Summary

Shattuck Labs beats Immuneering on 9 of the 14 factors compared between the two stocks.

About Shattuck Labs

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.